Internal Medicine · Horsham, PA
NPI
1194136077
Since 2014
Specialty
Internal Medicine
Code 207R00000X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
118 Welsh Rd Unit A
Horsham, PA, 19044
Phone (215) 657-5200
Groups this clinician bills Medicare through
Medicare paid, 2024
$66K
1,562 services
Medicare patients, 2024
289
Average age 72
Drug cost, 2024
$942K
1,752 prescriptions
Company payments, 2025
$904
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Deepika Nandiraju was code 99214 (office e&m - established), 272 times for 161 patients. In total Deepika Nandiraju billed 1,562 services in 18 codes, and Medicare paid $66K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-01-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 272 | 161 | $92.56 | $25K |
| 99232 Hospital E&M - Subsequent | Facility | 139 | 62 | $58.98 | $8,199 |
| 95251 Test - Miscellaneous | Office | 68 | 39 | $24.56 | $1,670 |
| 99222 Hospital E&M - Initial | Facility | 52 | 50 | $101.86 | $5,297 |
| 99204 Office E&M - New | Office | 51 | 51 | $109.00 | $5,559 |
| 96372 Injection Administration | Office | 14 | 12 | $11.72 | $164 |
| 99215 Office E&M - Established | Office | 13 | 13 | $147.17 | $1,913 |
By year: 2022 $30K for 348 services; 2023 $55K for 1,073 services; 2024 $66K for 1,562 services.
Medicare prescription drug claims, 2024
In 2024, the drug Deepika Nandiraju prescribed most often to Medicare patients was Levothyroxine Sodium, with 172 prescriptions and refills. In total Deepika Nandiraju wrote 1,752 Medicare prescriptions that cost $942K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 172 | 461 | 54 | $2,224 |
| Metformin Hcl Generic | 119 | 307 | 40 | $1,491 |
| Mounjaro Tirzepatide | 112 | 184 | 32 | $194K |
| Jardiance Empagliflozin | 102 | 207 | 33 | $117K |
| Ozempic Semaglutide | 99 | 145 | 28 | $133K |
| Metformin Hcl Er Metformin Hcl | 83 | 239 | 35 | $1,652 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 77 | 200 | 31 | $8,848 |
| Rybelsus Semaglutide | 70 | 106 | 15 | $96K |
| Synthroid Levothyroxine Sodium | 58 | 147 | 20 | $4,979 |
| Trulicity Dulaglutide | 58 | 92 | 11 | $92K |
| Glipizide Er Glipizide | 53 | 147 | 18 | $1,282 |
| Repaglinide Generic | 47 | 134 | 21 | $3,261 |
| Januvia Sitagliptin Phosphate | 43 | 110 | 15 | $53K |
| Methimazole Generic | 32 | 93 | 12 | $455 |
| Pioglitazone Hcl Generic | 31 | 94 | 17 | $624 |
Brand drugs: 936 claims; generic drugs: 718 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Deepika Nandiraju $904 ($904 in general payments such as food, travel and fees) from 5 companies. The largest payer was Medtronic, Inc. with $437.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.